1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 19,200 | 19,700 | 13:04 | |
| 19,200 | 19,700 | 07.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| Di | Spyre Therapeutics GAAP EPS of -$0.15 beats by $0.61 | 6 | Seeking Alpha | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Spyre Therapeutics reports positive interim data for IBD drug SPY003 | 2 | Investing.com | ||
| Di | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody | 9 | GlobeNewswire (Europe) | SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (a4ß7 +... ► Artikel lesen | |
| Di | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Di | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 | 1 | GlobeNewswire (USA) | ||
| 15.10. | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million | 1 | GlobeNewswire (USA) | ||
| 14.10. | Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing | 1 | RTTNews | ||
| 14.10. | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M | 1 | Seeking Alpha | ||
| 14.10. | Spyre Therapeutics legt Preis für Aktienangebot auf 18,50 US-Dollar fest | 1 | Investing.com Deutsch | ||
| 14.10. | Spyre Therapeutics prices public offering at $18.50 per share | 2 | Investing.com | ||
| 14.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 13.10. | Spyre Therapeutics announces public offering of common stock and pre-funded warrants | 1 | Seeking Alpha | ||
| 13.10. | Spyre Therapeutics announces common stock offering | 1 | Investing.com | ||
| 13.10. | Spyre Therapeutics kündigt öffentliche Platzierung von Stammaktien an | 2 | Investing.com Deutsch | ||
| 13.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 10.10. | IBM introduces Spyre AI accelerator to market | 6 | eeNews Europe | ||
| 08.10. | IBM's big iron to get Spyre AI accelerator upgrade this month | 12 | The Register |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 23,800 | -0,83 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 | Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 68,00 | +3,82 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous ... | DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 30,800 | -2,53 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results | Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy... ► Artikel lesen | |
| JOUNCE THERAPEUTICS | - | - | IBM's Red Hat acquires stealth Israeli startup Jounce for $20M to bolster AI cloud stack | ||
| LENZ THERAPEUTICS | 22,970 | -0,22 % | LENZ Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| QIAGEN | 37,335 | -0,05 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf
QIAGEN N.V.: QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück... ► Artikel lesen | |
| EVOTEC | 5,236 | -10,00 % | EQS-News: Evotec SE: In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,180 | -1,46 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,82 | +0,06 % | Chardan Capital downgrades Avidity Biosciences stock on Novartis acquisition | ||
| RECURSION PHARMACEUTICALS | 4,630 | +0,22 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| MBX BIOSCIENCES | 25,570 | +3,40 % | MBX Biosciences, Inc.: MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Reported positive topline results from the Phase 2 Avail trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross... ► Artikel lesen | |
| BIONTECH | 89,05 | -0,22 % | Biontech öffnet seine Bücher | MAINZ (dpa-AFX) - Nach der Verkündung mehrerer größerer Deals wird das Pharmaunternehmen Biontech an diesem Montag frische Geschäftszahlen vorlegen. Äußern dürften sich die Mainzer bei der Vorlage... ► Artikel lesen | |
| DISC MEDICINE | 83,85 | -3,62 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,520 | +3,49 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| KINIKSA PHARMACEUTICALS | 38,370 | -0,67 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen |
SPYRE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -5,13 % bei einem Aktienkurs von 18,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.